La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
MannKind Gestion
Gestion contrôle des critères 4/4
Le PDG MannKind's est Michael Castagna, nommé en May2017, a un mandat de 7.25 ans. La rémunération annuelle totale est $ 7.07M, composée du salaire de 9.9% et des bonus 90.1%, y compris les actions et options de la société. détient directement 0.9% des actions de la société, d'une valeur de $ 12.69M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 7.1 ans et 5.2 ans.
Informations clés
Michael Castagna
Directeur général
US$7.1m
Rémunération totale
| Pourcentage du salaire du PDG | 9.9% |
| Durée du mandat du directeur général | 7.3yrs |
| Propriété du PDG | 0.8% |
| Durée moyenne d'occupation des postes de direction | 7.2yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5.3yrs |
Mises à jour récentes de la gestion
Recent updates
MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 18
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Jul 17MannKind Outperforms As Tyvaso DPI Captures Market Share
May 15This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year
Mar 03MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement
Mar 02MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
Feb 15MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking
Jan 03Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price
May 15MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price
Jan 27Mannkind Corporation: Ready For Your Biotech Portfolio
Sep 01New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)
Aug 19MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed
Aug 09MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?
Feb 25MannKind: A Promising Player In The Inhalable Insulin Market
Feb 08US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results
Aug 14Lytham Partners Summer 2021 Investor Conference
Jun 14MannKind (MNKD) Investor Presentation - Slideshow
Jun 04MannKind reduces debt by $49.5M and restructures remaining obligations
Apr 26Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?
Feb 22MannKind to co-promote Thyquidity
Dec 17MannKind (MNKD) earns $12.5M milestone under licensing deal for treprostinil
Nov 20Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$12m |
| Mar 31 2024 | n/a | n/a | US$8m |
| Dec 31 2023 | US$7m | US$702k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$31m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$4m | US$623k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$98m |
| Jun 30 2022 | n/a | n/a | -US$88m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$4m | US$598k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$86m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$4m | US$495k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$45m |
| Jun 30 2020 | n/a | n/a | -US$44m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$2m | US$511k | -US$52m |
| Sep 30 2019 | n/a | n/a | -US$47m |
| Jun 30 2019 | n/a | n/a | -US$61m |
| Mar 31 2019 | n/a | n/a | -US$71m |
| Dec 31 2018 | US$2m | US$500k | -US$87m |
| Sep 30 2018 | n/a | n/a | -US$110m |
| Jun 30 2018 | n/a | n/a | -US$119m |
| Mar 31 2018 | n/a | n/a | -US$131m |
| Dec 31 2017 | US$1m | US$459k | -US$117m |
Rémunération vs marché: La rémunération totale de Michael ($USD 7.07M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 5.62M ).
Rémunération et revenus: La rémunération de Michael a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Michael Castagna (47 yo)
7.3yrs
Titularisation
US$7,068,114
Compensation
Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Director | 7.3yrs | US$7.07m | 0.83% $ 14.2m | |
| Chief Operating Officer | 1.5yrs | US$2.74m | 0.026% $ 436.0k | |
| Executive VP | 22.7yrs | US$2.34m | 0.17% $ 2.8m | |
| Executive VP and Chief People & Workplace Officer | 7.8yrs | US$2.22m | 0.24% $ 4.0m | |
| Executive Vice President of Special Projects | less than a year | US$2.34m | 0.20% $ 3.4m | |
| Chief Financial Officer | less than a year | pas de données | pas de données | |
| Executive Vice President of Technical Operations | 1.9yrs | US$1.12m | 0.021% $ 359.9k | |
| VP of Investor Relations & Treasury | 7.2yrs | US$519.59k | pas de données | |
| Senior Vice President of Worldwide Regulatory Affairs | 18.9yrs | pas de données | pas de données | |
| Chief Commercial Officer | 7.2yrs | US$921.51k | pas de données | |
| Executive VP of Research & Development and Chief Medical Officer | 1.3yrs | pas de données | 0.071% $ 1.2m |
7.2yrs
Durée moyenne de l'emploi
58yo
Âge moyen
Gestion expérimentée: L'équipe de direction de MNKD est chevronnée et expérimentée (ancienneté moyenne 7.1 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Director | 7.3yrs | US$7.07m | 0.83% $ 14.2m | |
| Independent Director | 20.9yrs | US$241.73k | 0.043% $ 734.3k | |
| Independent Director | 20.3yrs | US$240.64k | 0.096% $ 1.6m | |
| Independent Director | 5.8yrs | US$226.73k | 0.010% $ 171.5k | |
| Independent Director | 20.8yrs | US$229.23k | 0.0054% $ 92.8k | |
| Independent Director | 4.7yrs | US$233.14k | 0.064% $ 1.1m | |
| Independent Chairman | 9.3yrs | US$255.64k | 0.0089% $ 151.6k | |
| Independent Director | 3.8yrs | US$221.73k | 0.039% $ 663.6k | |
| Member of Scientific Advisory Board | 3.1yrs | pas de données | pas de données | |
| Independent Director | 4.5yrs | US$221.73k | 0.040% $ 686.4k | |
| Member of Scientific Advisory Board | 3.1yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 3.1yrs | pas de données | pas de données |
5.3yrs
Durée moyenne de l'emploi
68yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de MNKD sont considérés comme expérimentés (ancienneté moyenne 5.2 ans).